Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Terns Pharmaceuticals Inc. currently manages 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 5 distinct art units. This means that almost every pending matter is being reviewed by a different examiner in a different specialized division of the USPTO. With 6 pending office actions spread across 5 distinct art units, the company must adapt its prosecution strategy to the varied requirements of multiple pharmaceutical examination groups.
The busiest examiner, WELLS, LAUREN QUINLAN, has 1 pending office action, matching the workload of the other 5 examiners. This profile reflects a moderate volume of activity with a significant level of technical and administrative dispersion. Since there are 6 distinct examiners involved, no single individual has a controlling influence over the 6 pending office actions. Practitioners should focus on the specific guidelines of the 5 distinct art units to ensure consistent results across this decentralized biotechnology portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| Double-patenting only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| JAIN, AVEESH | 1 | — | — |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548650 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | 26d |
| 18976460 | TREATING LIVER DISORDERS WITH AN SSAO INHIBITOR | WELLS, LAUREN QUINLAN | — |
| 18956385 | COMPOUNDS AS GLP-1R AGONISTS | SEITZ, ANTHONY JOSEPH | — |
| 18622057 | COMPOUNDS AS GLP-1R AGONISTS | ROZOF, TIMOTHY R | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1621 | 1 |
| 4100 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18976460 | TREATING LIVER DISORDERS WITH AN SSAO INHIBITOR | WELLS, LAUREN QUINLAN | — | §103 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18956385 | COMPOUNDS AS GLP-1R AGONISTS | SEITZ, ANTHONY JOSEPH | 1629 | DP | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18651843 | TREATMENT OF LIVER DISORDERS WITH A THR-ß AGONIST | YOO, SUN JAE | 1621 | §103 | Non-Final OA | — | Pending | May 01, 2024 |
| 18629151 | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF | JAIN, AVEESH | 4100 | §103Other | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18622057 | COMPOUNDS AS GLP-1R AGONISTS | ROZOF, TIMOTHY R | 1625 | §102DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18548650 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | 1627 | DP | Final Rejection | 26d | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTerns Pharmaceuticals Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Lauren Quinlan Wells has the most, with 1 of Terns Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
